La vendita allo scoperto per Legend Biotech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Legend Biotech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Legend Biotech (NASDAQ:LEGN) Azioni, Report sulle vendite allo scoperto

Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech Corporation - American Depositary Shares

Legend Biotech Corp

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at upcoming medical congresses
SPRING HOUSE, Pa., Nov. 18, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced positive topline results from <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=1172454155&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095115&amp;a=ICONIC-LEAD">ICONIC-LEAD</a>a, a&nbsp;pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 and response rates continued to improve through week 24.1
Once daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds (64.7%) of patients treated with&nbsp;icotrokinra achieved IGA scores of 0/1 (clear or almost clear skin), and 49.6% achieved PASI 90, compared to 8.3% and 4.4% on placebo, respectively.1 Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9%&nbsp;achieving PASI 90.1&nbsp;Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. A similar proportion of patients experienced adverse events (AEs) between icotrokinra and placebo, with 49.3% and 49.1% of participants experiencing a treatment emergent adverse event (TEAE) at week 16.1,2,3
Furthermore, positive topline results from the Phase 3 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=4201851419&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095102&amp;a=ICONIC-TOTAL">ICONIC-TOTAL</a>d&nbsp;study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.4 Comprehensive results from ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions.

Biotech

News

General

Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With Moderate To Severe Plaque Psoriasis; Met Its Co-Primary Endpoints In Patients With Moderate To Severe Plaque Psoriasis; 74% Of Patients Achieved Clear Or Almost Clear Skin At Week 24

Guidance

Archer-Daniels Midland Sees FY24 Adj. EPS $4.50-$5.00 Vs $4.60 Est.

Berquist, who succeeds Andy Tometich as Chief Executive Officer&nbsp;and President, most recently served as Executive Vice President and Chief Commercial Officer for Quaker Houghton.

Management

Quaker Houghton Board Appoints Joseph Berquist As CEO And President, And A Member Of Board, Effective Immediately

Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) reported quarterly earnings of $1.09 per share which missed the analyst consensus estimate of $1.25 by 12.8 percent. The company reported quarterly sales of $19.937 billion which missed the analyst consensus estimate of $21.345 billion by 6.59 percent. This is a 8.10 percent decrease over sales of $21.695 billion the same period last year.

Earnings

Earnings Misses

Archer-Daniels Midland Q3 2024 Adj. EPS $1.09 Misses $1.25 Estimate, Sales $19.937B Miss $21.345B Estimate

Wendy's Appoints Ken Cook As CFO, Effective Dec. 2

Piper Sandler analyst Christopher Raymond upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Overweight and raises the price target from $3 to $13.

Upgrades

Price Target

Analyst Ratings

ACRS

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13

Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42048131/symbotic-reports-fourth-quarter-and-fiscal-year-2024-results">details from the report.&nbsp;</a>
The Details:&nbsp;Symbotic reported quarterly earnings of five cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue came in at $576.76 million, which beat the analyst consensus estimate of $470.27 million and is an increase over sales of $391.88 million from the same period last year.
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
&#8220;I&#8217;m pleased with our performance this year, as our focus on innovation and customer success has delivered robust growth. This year&#8217;s results, driven by the hard work and dedication of our team, underscore the strength of our long-term strategy and commitment to driving sustainable, long-term growth for our customers, shareholders, and employees,&#8221; said Rick Cohen, CEO of Symbotic. 
Outlook:&nbsp;For the first quarter of fiscal 2025, Symbotic expects revenue of $495 million to $515 million, versus the $495.73 million estimate, and adjusted EBITDA of $27 million to $31 million.
SYM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Symbotic shares are up 23.21% after-hours at $37.44 at the time of publication Monday.&nbsp;
Read More:  • <a href="https://www.benzinga.com/24/11/42047989/walmart-q3-earnings-preview-will-eps-beat-streak-continue-analysts-says-retailer-should-remain-a-core-holding">Will Walmart&#8217;s Streak Of Earnings Beats Continue Tuesday? Analysts Say Retailer A &#8216;Core Holding&#8217;</a>
Photo: Courtesy of Symbotic, Inc.

After-Hours Center

Movers

Symbotic Stock Rallies After Strong Q4 Results: Details

AMD Announces Darla Smith Resigns As Chief Accounting Officer, To Remain VP Until January 2025; Philip Carter Appointed As New Chief Accounting Officer

GBDC

Golub Capital BDC Reveals Series Of Debt Funding Structure Initiatives Expected To Reduce  Prospective Borrowing Costs And Provide Investment Flexibility

Investors and speculators are gearing up for Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) earnings report on Wednesday, an event that&#8217;s expected to send ripples, if not tidal waves, <a href="https://www.benzinga.com/markets">across the U.S. stock market. </a>
If the options market is right, Nvidia's results could spark moves in the S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – larger than those typically triggered by key economic data like the employment and inflation reports.
Nvidia's dominance in the AI-driven technology trade has turned its earnings into a barometer for overall market sentiment, and its influence on the stock market is unparalleled.
Over the past year, Nvidia accounted for 20% of the S&amp;P 500's total returns and Bank of America's derivatives analyst Gonzalo Asis didn't mince words: &#8220;It remains the most dominant stock in the market… expected to drive nearly 25% of the S&amp;P 500&#8217;s EPS growth in 3Q.&#8221;
In essence, whether Nvidia beats or misses expectations, the ripple effects will likely extend far beyond its ticker.
<h3 class="wp-block-heading">S&amp;P 500 Implied Move Is Higher Than Inflation Or Jobs Data</h3>
The options market implies a potential 1.05% move in the S&amp;P 500—higher than what traders expect from next month's Non-Farm Payroll (NFP) data, Consumer Price Index (CPI) print, and in line with the Federal Reserve&#8217;s December meeting.
&#8220;Options are assigning more broad-market risk around NVDA earnings than around next month&#8217;s NFP and CPI days, and as much as the Dec FOMC,&#8221; the analyst noted.
For Nvidia shares themselves, the implied one-day move is even more eye-popping: 12.5%.
&#8220;We remain cautious of fragility risks in single names around earnings, but NVDA hedges themselves are not particularly cheap relative to how much the stock has reacted to results in the last two years,&#8221; Assis wrote.
The analyst also warned that the recent easing of post-election euphoria and heightened single-stock fragility can be reasons for traders to hedge against potential market turbulence if Nvidia disappoints.
<h3 class="wp-block-heading">A Strategy For Hedging The Nasdaq Impact</h3>
For traders seeking to hedge the broader market risks tied to Nvidia&#8217;s performance, Bank of America recommended an option strategy using put spreads on the Nasdaq-100 ETF, the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). Specifically, the QQQ 22Nov 490-480 put spreads are priced at $2 and could offer a 5x payout if the Nasdaq-100 falls by roughly 3.3% this week.
Despite the potential need for hedges, the bank also noted that hedging NVDA earnings directly is not cheap, considering how significantly the stock has reacted to its last few earnings reports.
<h3 class="wp-block-heading">Historical Nvidia Earnings Data</h3>
Data from <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">Benzinga Pro</a> shows that over the last 12 quarters, Nvidia has exceeded earnings-per-share (EPS) expectations 10 times and missed revenue expectations only once. 
On average, Nvidia shares moved 5.3% in the single trading day following its earnings release.
The largest 1-day gain followed its first quarter 2024 earnings, when the stock surged 24.4%, while the worst reaction occurred after fourth quarter 2024 results, with a decline of 7.6%. 
Here's a snapshot of the company's recent earnings performance:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Fiscal Quarter</th>
<th>Date Announced</th>
<th>Surprise % EPS</th>
<th>Surprise % Revenue</th>
<th>1-Day % NVDA Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2-2025</td>
<td>8/28/24</td>
<td>6.25%</td>
<td>4.73%</td>
<td>-6.38%</td>
</tr>
<tr>
<td>Q1-2025</td>
<td>5/22/24</td>
<td>2.86%</td>
<td>5.66%</td>
<td>9.32%</td>
</tr>
<tr>
<td>Q4-2024</td>
<td>2/21/24</td>
<td>11.45%</td>
<td>7.19%</td>
<td>16.40%</td>
</tr>
<tr>
<td>Q3-2024</td>
<td>11/21/23</td>
<td>19.64%</td>
<td>12.39%</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Q2-2024</td>
<td>8/23/23</td>
<td>29.19%</td>
<td>20.38%</td>
<td>0.10%</td>
</tr>
<tr>
<td>Q1-2024</td>
<td>5/24/23</td>
<td>18.48%</td>
<td>10.31%</td>
<td>24.37%</td>
</tr>
<tr>
<td>Q4-2023</td>
<td>2/22/23</td>
<td>8.64%</td>
<td>0.68%</td>
<td>14.02%</td>
</tr>
<tr>
<td>Q3-2023</td>
<td>11/16/22</td>
<td>-15.94%</td>
<td>2.79%</td>
<td>-1.46%</td>
</tr>
<tr>
<td>Q2-2023</td>
<td>8/24/22</td>
<td>-59.20%</td>
<td>-17.23%</td>
<td>4.01%</td>
</tr>
<tr>
<td>Q1-2023</td>
<td>5/25/22</td>
<td>5.43%</td>
<td>2.07%</td>
<td>5.16%</td>
</tr>
<tr>
<td>Q4-2022</td>
<td>2/16/22</td>
<td>8.20%</td>
<td>3.01%</td>
<td>-7.56%</td>
</tr>
<tr>
<td>Q3-2022</td>
<td>11/17/21</td>
<td>6.36%</td>
<td>4.00%</td>
<td>8.25%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Benzinga Pro</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">Inflation Could Surge To 3% If Trump Applies Universal Tariffs: Goldman Sachs</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Broad U.S. Equity ETFs

Previews

Options

Econ #s

Economics

Federal Reserve

Tech

ETFs

NVDA

Why Nvidia Earnings May Trigger Massive S&P 500 Volatility

Current CEO Lou Haddad will retire at the end of 2024 but will retain the role of Executive Chairman of the Company's Board of Directors. Additionally, the Board of Directors expects to appoint Tibbetts to the Board of Directors upon his elevation to Chief Executive Officer.

Armada Hoffler Names Shawn Tibbetts As CEO, Effective January 1, 2025; Current CEO Lou Haddad To Retain The Role Of Executive Chairman

-The New York Stock Exchange ("NYSE", the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Spirit Airlines, Inc. (the "Company") — ticker symbol SAVE — from the NYSE. Trading in the Company's common stock will be suspended immediately.
NYSE Regulation reached its decision that the Company is no longer suitable for listing pursuant to NYSE Listed Company Manual Section 802.01D after the Company's November 18, 2024 press release and Form 8-K disclosures that the Company has commenced a prearranged chapter 11 process in the United States Bankruptcy Court for the Southern District of New York. In reaching its delisting determination, NYSE Regulation notes the Company disclosed that all of the Company's existing common stock and other equity interests will be cancelled without any distributions to the holders of such common stock and other equity interests on account thereof.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

SAVE

NYSE To Commence Delisting Proceedings Against Spirit Airlines, Effective Immediately

Healthpeak Properties Raises FY24 AFFO From $1.56-$1.58 To $1.57-$1.59

MCHP

Microchip Technology Announces Ganesh Moorthy Is Retiring As CEO, President And Board Member; Steve Sanghi Appointed Interim CEO

Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre.&nbsp;
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC, Goldman Sachs &amp; Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC are acting as the joint book-running managers for the proposed offering. LifeSci Capital LLC is acting as lead manager for the proposed offering.

Offerings

SYRE

Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants

WIIM

OMCL

Omnicell shares are trading lower after the company announced a proposed private placement of $150 million in convertible senior notes.

Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) ("Omnicell") today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes.
The notes will be general unsecured, senior obligations of Omnicell, will accrue interest payable semiannually in arrears and will mature on December 1, 2029, unless earlier converted, redeemed or repurchased. Upon conversion, Omnicell will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Omnicell's common stock or a combination of cash and shares of Omnicell's common stock, at Omnicell's election, in respect of the remainder, if any, of Omnicell's conversion obligation in excess of the aggregate principal amount of the notes being converted. The interest rate, initial conversion rate, redemption or repurchase rights and other terms of the notes will be determined at the time of pricing of the offering.

Omnicell Announces Proposed Private Placement Of $150M Of Convertible Senior Notes Due 2029

Donald Trump was viewed as the more pro-cryptocurrency presidential candidate in the 2024 election and his support for crypto could get another push with a report that his media company is acquiring a<a href="https://www.benzinga.com/markets/cryptocurrency/21/01/19071375/spac-surges-64-on-report-of-merger-talks-with-ice-owned-crypto-exchange-bakkt"> cryptocurrency trading company.</a>
What Happened: Shares of Bakkt Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NASDAQ">BKKT</a>) are soaring Monday on reports the cryptocurrency company, <a href="https://www.benzinga.com/markets/cryptocurrency/21/04/20550003/3-cryptocurrency-spacs-that-could-run-on-a-successful-coinbase-ipo">which went public </a>in October 2021 via SPAC merger, is being acquired by Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>).
The media company co-founded by Trump, which owns the Truth Social platform, is in advanced talks to acquire Bakkt, <a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">according </a>to the Financial Times. The report said Trump Media &amp; Technology Group would acquire the cryptocurrency company, which is backed by Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), in an all-share deal.
Benzinga reached out to Trump Media &amp; Technology Group for comment on the report and will update the story accordingly. Benzinga has also contacted Bakkt for comment. 
Bakkt's first CEO was Kelly Loeffler, who was previously a member of the U.S. Senate, representing the state of Georgia as a Republican. Loeffler is helping to organize Trump's inauguration in January and has close ties to the president-elect.
The Intercontinental Exchange, which owns the New York Stock Exchange, owns a reported 55% of Bakkt. The exchange company would have to give approval to any such sale to the Trump media company.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Bakkt <a href="https://www.benzinga.com/news/24/06/39234822/bakkt-holdings-explores-potential-sale-or-breakup-amid-crypto-sector-consolidation">said in June</a> it was exploring strategic alternatives that could include a sale or breakup of the company.
The company previously said its crypto custody business could be wound down. This segment might not be included in the buyout, according to the report. Bakkt is planning to build a crypto trading platform geared to institutional investors.
DJT shares have experienced high volatility and an increased valuation after Trump won the 2024 election.
Trump's <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41096120/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-he-wasnt-a-fan-heres-how-much-youd">pro-crypto stance</a> may have helped elevate Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to all-time highs following his <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">2024 election win.</a>
An acquisition of Bakkt would push Trump's media company and the president-elect deeper into the cryptocurrency sector, which comes after he promoted a crypto venture called World Liberty Financial with business partners.
BKKT, DJT Price Action: Bakkt stock was halted several times after the report and ended Monday&#8217;s session 163.04% higher at $29.71 versus a 52-week trading range of $5.57 to $68.75. Bakkt shares are down 44% year-to-date in 2024.
Trump Media &amp; Technology stock is up 16.65% to $32.78 Monday versus a 52-week trading range of $22.55 to $79.38. Trump Media &amp; Technology stock is up 85% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">DJT Stock Volatile On Election Day: Donald Trump&#8217;s Media Company Reports Q3 Earnings, Growth Initiatives</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Politics

Trading Ideas

$BTC

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Trump Digs Deeper Into Cryptocurrency? Bakkt Shares Soar On Reported Interest From President-Elect's Media Company

The consolidation of the Company's welded wire manufacturing operations is expected to result in the elimination of up to 35 positions at the Warren facility. It is anticipated that operations at the Warren facility will cease by the end of November 2024. Insteel expects to incur a restructuring charge of approximately $1.9 million related to the facility's closure.

IIIN

Insteel Industries Plans Closing Its Facility In Warren, Ohio; Resulting In Elimination Of Up To 35 Positions; Expects To Incur Restructuring Charge Of $1.9M

Fiscal 2025 Financial Guidance
<ul>
<li>AECOM expects to deliver record net service revenue and profitability, margins and continued strong cash flow conversion, including:
<ul>
<li>Organic NSR2 growth of 5% to 8%.
<ul>
<li>Expect phasing to follow a normal seasonal pattern with accelerating growth as the year progresses.</li>
</ul>
</li>
<li>Adjusted1 EBITDA4 of between $1,170 million and $1,210 million, reflecting an increase of 9% at the mid-point over fiscal 2024.</li>
<li>An adjusted EBITDA margin5 of 16.3%, representing a 30 basis point increase from fiscal 2024.</li>
<li>Adjusted1 EPS of between $5.00 and $5.20, reflecting an increase of 13% at the mid-point compared to fiscal 2024.</li>
<li>100%+ free cash flow6 conversion.</li>
</ul>
</li>
<li>Other assumptions incorporated into guidance:
<ul>
<li>An average fully diluted share count of 134 million, which reflects only shares repurchased to-date, though the Company intends to continue repurchasing stock that would provide a benefit to per share earnings.</li>
<li>An adjusted effective tax rate of approximately 24% for the full year.
<ul>
<li>The Company expects to maintain an approximately 24% tax rate for the next several years.</li>
</ul>
</li>
</ul>
</li>
<li>See the Regulation G Information tables at the end of this release for a reconciliation of non-GAAP measures to the most directly comparable GAAP measures.</li>
</ul>
Long-Term Financial Framework for Value Creation
<ul>
<li>The Company's long-term financial framework includes expectations to deliver annually:
<ul>
<li>Organic NSR2 growth of 5% to 8%.</li>
<li>At least 20 to 30 basis points of adjusted EBITDA margin5 expansion.</li>
<li>At least 100% conversion of adjusted net income to free cash flow6.</li>
<li>Double-digit adjusted EPS1 and free cash flow6 per share growth.</li>
</ul>
</li>
<li>The Company also expects to achieve an at least 17% adjusted EBITDA margin5 exiting fiscal year 2025 and an at least 25% ROIC9 over the long term.</li>
</ul>

AECOM Long-term Financial Framework Includes Expectations To Deliver Annually: Organic NSR Growth Of 5%-8%; At Least 20 To 30 Basis Points Of Adjusted EBITDA Margin Expansion; At Least 100% Conversion Of Adjusted Net Income To Free Cash Flow; Double-Digit Adjusted EPS And Free Cash Flow Per Share Growth; Expects To Achieve An At Least 17% Adjusted EBITDA Margin Exiting Fiscal Year 2025 And An At Least 25% ROIC Over The Long Term

In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The company's share...

Legend Biotech (LEGN) Gets a Hold from William Blair

Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript

Legend Biotech Corporation ( ($LEGN) ) has released its Q3 earnings. Here is a breakdown of the information Legend Biotech Corporation presented to...

Legend Biotech's Q3 2024 Sees Strong Sales Growth

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TScan Therapeutics (TCRX – Research Report), Legend ...

Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)

BMO Capital analyst Kostas Biliouris reiterated a Buy rating on Legend Biotech (LEGN – Research Report) yesterday and set a price target of $90.00....

Strong Market Position and Future Potential of Legend Biotech Driven by Carvykti's Success

Johnson & Johnson: Tracking Well Above The Industry

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report). The compan...

Legend Biotech (LEGN) Gets a Buy from Truist Financial

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price tar...

Morgan Stanley Remains a Buy on Legend Biotech (LEGN)

Bristol-Myers Squibb: Buy This Bargain Before It's Gone

Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA

ABBV

ALVO

ALVOW

AMGN

ARGX

AZNCF

BEIGF

BGNE

BMYMP

BRDCY

FUJHY

ICUI

KWEB

LEGN

LNVGY

MCHI

NVSEF

REGN

SPGI

SVNDY

TCRX

UPRO

VTRS

Health Care

Press Releases

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Comments

Legend Biotech

Vendite allo scoperto

Legend Biotech (NASDAQ:LEGN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO